PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of mayoclinprocLink to Publisher's site
 
Mayo Clin Proc. 2011 September; 86(9): 885–893.
PMCID: PMC3257991

Perioperative Cognitive Decline in the Aging Population

Abstract

Elderly patients who have an acute illness or who undergo surgery often experience cognitive decline. The pathophysiologic mechanisms that cause neurodegeneration resulting in cognitive decline, including protein deposition and neuroinflammation, also play a role in animal models of surgery-induced cognitive decline. With the aging of the population, surgical candidates of advanced age with underlying neurodegeneration are encountered more often, raising concerns that, in patients with this combination, cognitive function will precipitously decline postoperatively. This special article is based on a symposium that the University of California, San Francisco, convened to explore the contributions of surgery and anesthesia to the development of cognitive decline in the aged patient. A road map to further elucidate the mechanisms, diagnosis, risk factors, mitigation, and treatment of postoperative cognitive decline in the elderly is provided.

Aβ = β-amyloid; AD = Alzheimer disease; apoE = apolipoprotein E; APP = amyloid precursor protein; DAMPs = damage-associated molecular patterns; HMGB-1 = high mobility group box chromosomal protein 1; IL = interleukin; POCD = postoperative cognitive dysfunction; PRR = pattern recognition receptor; TLR = toll-like receptor

Cognitive decline, including memory dysfunction, is a leading cause of functional impairment worldwide. The risk of cognitive decline increases with age and is further enhanced after hospitalization for critical illness and surgery, resulting in significant long-term morbidity and an overall reduced quality of life.1 The maintenance and/or restoration of functional independence, including cognition, in the elderly hospitalized patient constitutes a major challenge for the health care system. It is projected that patients older than 65 years will become the largest segment of the surgical population by 2020.2 Recent advances in technology and anesthetic care have enabled increasingly older and sicker patients to be viable candidates for elective surgery; of particular concern are surgical patients with preexisting neurodegenerative conditions in whom a precipitous decline in cognitive function may occur postoperatively. The most prevalent neurodegenerative condition is Alzheimer disease (AD); it is estimated to affect 35 million people worldwide, of which 5.5 million reside in the United States.3 Because of the steady growth of the proportion of elderly individuals in developed countries, a 4-fold increase in AD is projected to occur by 2050.4,5

Persistent memory and learning disabilities may occur postoperatively and may be related to neurodegenerative processes. The observation that after an operation some patients are more likely to experience cognitive deterioration and personality changes has long been described. In 1887, George Savage6 described how surgery and anesthesia may possibly contribute to the development of “mental insanity.” Despite these early observations of perioperative cognitive decline as a hazard of surgery, no rigorous investigations were performed until the past decade, in which reports have focused on the role of anesthesia and surgery as possible causes of cognitive dysfunction.7-9

Postoperative cognitive decline (POCD) broadly follows 2 different patterns: acute cognitive dysfunction, also known as early postoperative delirium, and a later onset and more persistent POCD.10 Delirium is often seen in older patients after hospitalization and surgery11; the classic features are an acute change in mental status, inattention, disorganized thinking, and altered consciousness. Delirious patients exhibit a spectrum of behaviors that range from hyperactive to hypoactive, with the latter being more common in postoperative patients. Although often of short duration, delirium is associated with increased mortality,12 greater care dependency, costs,13 and prolonged hospitalization.14 Persistent cognitive decline and functional impairments are also associated with hospitalization in survivors of acute illness and sepsis.15 Because of the dynamic and complex processes that underlie this condition, many strategies are being contemplated for the prevention and treatment of delirium, especially in older patients who are at higher risk16 (Table 1).

TABLE 1.
Risk Factors for Development of Postoperative Delirium

As yet, no therapeutic interventions are available that prevent the onset of postoperative delirium. Marcantonio et al32 and others33 have developed and validated a scoring system to predict the possible onset of delirium before surgery. They report a 9% incidence of delirium in elective noncardiac, nonorthopedic patients within the first 5 postoperative days; after orthopedic procedures, the incidence increases to 41%. Emergency surgery in the elderly is also associated with a higher incidence of acute cognitive decline, ranging from 42.3% after surgery for lower limb ischemia to 73% after lung transplant.34,35

Postoperative cognitive dysfunction is a more subtle and prolonged change in cognition, with clinical manifestations similar to those seen in neurodegenerative disorders, and is diagnosed by neuropsychological testing. Although POCD is not listed in the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), it has been defined as a “more than expected” postoperative deterioration in cognitive domains, including short- and long-term memory (ie, reduced ability to learn or recall information), mood, consciousness, and circadian rhythm.36 The precise threshold of deterioration and the number of domains that need to be affected are matters of debate.37 This neurocognitive impairment has been correlated with a longer hospitalization time, greater comorbidities, and higher mortality risk in patients who develop this complication compared with those who do not.38 Neurologic and cognitive complications were first described after cardiac surgery with cardiopulmonary bypass; however, POCD also affects patients after noncardiac procedures.39 An international multicenter study on POCD (ISPOCD) reported memory impairments in 25.8% of patients 1 week after noncardiac surgery and in 9.9% after 3 months in patients older than 60 years.8 Johnson et al40 reported a similar incidence, with almost 20% of middle-aged surgical patients experiencing cognitive decline 1 week after surgery compared with 4.0% in the nonsurgical control group. More recently, similar distribution patterns in type and severity of cognitive deficits were reported in a study group of 308 patients undergoing major surgery.41 At 3 months after surgery, 231 patients (75%) had normal levels of cognitive functions, 42 (13.6%) experienced memory decline but 26 (8.4%) showed only executive function impairment, and 9 (2.9%) experienced decline in both executive and memory domains. Some reports have described cognitive decline persisting up to 1 year after surgery; this may indicate a possible progression to dementia (Table 2).43 Of note, there is no certainty that this rate of cognitive dysfunction does not occur in surgical patients randomized not to have surgery.

TABLE 2.
Incidence of and Factors Associated With Postoperative Cognitive Dysfunction

Studies have sought to identify factors that may contribute to POCD, including exposure to general anesthesia,50 hyperventilation, hypotension, hypoxia, psychoactive drugs, and patient-related factors, including aging, genetic polymorphisms (APOE4),46,48 and comorbidities such as cancer and underlying neurodegenerative and neurovascular diseases.37 In a prospective study, patients who had previously experienced a stroke were more at risk for POCD even though they had no neurologic sequelae from the remote stroke event.42 Although age and surgery are consistently reported as important risk factors in the development of cognitive dysfunction, the etiology of perioperative cognitive decline remains unclear, and even its very existence is being debated.51 Studies exploring contributory factors have had methodological problems, including being underpowered and lacking in appropriate controls; furthermore, because of the difference in neurocognitive testing and thresholds for diagnosing cognitive dysfunction, comparison of studies and hence prioritization of risk factors have been difficult.37

Although perioperative cognitive decline and AD may share certain neuropathologic and biochemical mechanisms, there is no direct evidence linking the involvement of AD-type pathogenic mechanisms and POCD in humans and only weak epidemiological evidence associating surgery with onset of AD.52 It remains controversial whether perioperative cognitive decline increases the risk of further cognitive decline resulting in dementia, although neuropsychologists in clinical practice continually hear remarks that “the family member/friend has never been the same since the operation.” Epidemiological studies have suggested that neurodegenerative disorders, including AD, may be accelerated by surgery53 and that delirium exacerbates dementia in AD patients.54 However, Avidan et al,55 in a retrospective cohort study, reported no evidence of long-term cognitive decline after a surgical event and were unable to associate surgery or anesthesia with further dementia and AD. There are no data from studies to explore the possibility that surgery aggravates existing AD.

To examine the possible contribution of surgery and anesthesia to the development of cognitive changes and possible long-term consequence, the University of California, San Francisco, convened a state-of-the-science symposium on October 13, 2010, to discuss the putative relationship between neurodegeneration and perioperative cognitive changes in the aging population and to address the pathophysiology of these 2 conditions. Speakers in the symposium reviewed data from preclinical models and clinical studies and opined on translational approaches to understand the factors affecting postoperative cognitive decline. Additionally, to supplement this review with further up-to-date information, the authors undertook a literature search using PubMed with the following key words: Alzheimer's disease, anesthesia, delirium, dementia, postoperative cognitive dysfunction, and surgery.

SURGERY, INFLAMMATION, AND COGNITIVE DECLINE

Inflammation and activation of the immune system are associated with cognitive decline.56,57 Surgical patients exhibit elevations of proinflammatory cytokines in both the central nervous system and the systemic circulation, the extent of which may relate to the degree of cognitive decline.58,59 Major surgical procedures, such as cardiac surgery and orthopedic procedures in particular, expose the patient to extensive trauma, blood loss, and extensive tissue injury; products of these are capable of engaging with the innate immune system to induce an inflammatory response.60

Animal models have been useful in identifying mechanisms and putative targets for intervention and treatment of surgery-induced cognitive decline. Data from preclinical studies support the concept that inflammation is a possible pathogenic mechanism for postoperative cognitive decline and define a causative role for interleukin 1β (IL-1β) after surgery.57 Increased expression of IL-1β in the hippocampus of old mice undergoing minor surgery was associated with cognitive decline, corroborating the view that surgery-induced neuroinflammation can result in cognitive impairment.61 Sickness behavior, a related syndrome that occurs after acute illness, is characterized by a decline in cognitive function, fever, decreased food intake, somnolence, hyperalgesia, and general fatigue and is associated with a systemic cytokine release and neuroinflammation in the hippocampus, amygdala, and limbic system.62,63 On sensing changes in proinflammatory molecules and abnormal proteins, microglia (the resident immunocompetent cells) phenotypically shift from a resting state to one that is reactive.64 During activation, microglia undergo stereotypical conformational changes in both morphology and function.65 Although activated microglia may be protective through the release of neurotrophic and anti-inflammatory molecules, these cells also secrete proinflammatory cytokines (including IL-1 and tumor necrosis factor α),66 reactive oxygen species, excitotoxins (such as glutamate and adenosine triphosphate),67 chemokines, and neurotoxins, such as amyloid precursor protein (APP) and other pathologic proteins.68 Activated microglia can also inhibit neurogenesis in the hippocampus, thereby impairing synaptic plasticity and repair of neuronal dysfunction. Conditions that can convert the usually self-limiting postsurgical neuroinflammatory response into one that is persistent may include advanced age and underlying systemic disease, both of which may be associated with enhanced or prolonged inflammation after surgery.69 Furthermore, a normal neuroinflammatory response to surgery may have long-lasting detrimental effects in settings of underlying neuropathology, whether clinically evident or not.

A so-called danger signal is required to provoke the immune system into a response to the original threat70,71; surgery is a likely trigger of the danger signal (Figure). The initiating mechanism whereby surgical trauma stimulates innate immunity is likely to involve damage-associated molecular patterns (DAMPs), which are released from cells that are dead or dying due to non-apoptotic (ie, necrotic) processes.72 Among the DAMPs that can be released during surgical trauma is the high mobility group box chromosomal protein 1 (HMGB-1), which binds and signals through a family of evolutionarily conserved pattern recognition receptors (PRRs).73 Release of HMGB1 is both active and passive in many inflammatory conditions, ranging from sepsis to arthritis, acute lung injury, and stroke.74 Early activation of the innate immunity via DAMPs such as HMGB-1 and cytokines, including tumor necrosis factor α, appears to mediate the initial response to surgical trauma that leads to neuroinflammation and cognitive decline.56 Toll-like receptors (TLRs), part of the superfamily of PRRs, recognize a diverse range of ligands including pathogen-associated molecular patterns (PAMPs) and DAMPs.75,76 Each stimulated TLR activates distinct signaling pathways that increase synthesis and release of proinflammatory mediators. Toll-like receptor 4 is perhaps the most active interface that bridges microbial infection with inflammation.77,78 Its role after lipopolysaccharide endotoxemia has been extensively studied79; however, the pathways that regulate infection-induced neuroinflammation and cognitive decline appear to be different from those seen after aseptic surgical trauma.56 Endogenous inducers of the innate immune response engage not only TLRs but also other PRRs to perpetuate and amplify the inflammatory response.80 Advanced glycation end products, HMGB-1, and some S100β proteins activate the receptor for advanced glycation end products that may contribute to the signaling mechanism underlying cognitive decline, especially in the setting of comorbidities such as obesity and diabetes, which can enhance the risk of neurodegeneration including AD.81,82

FIGURE.
Factors and molecular events associated with the pathogenesis of cognitive decline. CNS = central nervous system; DAMPs = damage-associated molecular patterns; HMGB-1 = high mobility group box chromosomal protein 1; IL-1 = interleukin 1; PMN = polymorphonuclear ...

Like other inflammatory conditions, the neuroinflammation that occurs after surgery probably has 2 phases: proinflammatory and anti-inflammatory. The “switch” from the one to the other is likely to be under control of both neural and humoral factors83,84; abnormalities of the switching mechanism may cause a nonresolving chronic inflammatory state that could create the circumstances for persistent cognitive decline.

ANESTHETICS AND NEURODEGENERATION

Accumulation of abnormal proteins in the nervous system appears to be a pivotal mechanism for causing cognitive decline and memory disruption. Aggregation of naturally occurring peptides in the brain remains a hallmark for neurodegeneration, especially because these factors strongly correlate with both neurotoxicity and cell death.85 A relationship between anesthesia, β-amyloid (Aβ), and tau protein phosphorylation in particular has been suggested (and reviews have been published86-89). Specifically, the commonly used inhalation anesthetic isoflurane has been shown to enhance Aβ oligomerization in cultured cells.87 Isoflurane88,90 and another commonly used inhalation anesthetic, sevoflurane,91 but not desflurane,92 have been shown to enhance Aβ accumulation in vivo and in vitro. Interestingly, low concentration of isoflurane alone did not increase Aβ accumulation, but the combination of this low concentration of isoflurane with nitrous oxide did increase Aβ accumulation.93 Anesthetic-induced Aβ accumulation also is associated with caspase activation and apoptosis,94 and anesthesia-induced hypothermia has been shown to induce tau protein phosphorylation.89,95 However, the anesthetic propofol can also directly increase tau protein phosphorylation.96 Alternative findings that suggest that anesthesia is not associated with neurodegenerative diseases and/or that anesthetics do not promote neurodegeneration are summarized in 2 recent reviews.97,98

In addition to anesthesia-induced neurotoxicity in the newborn,99 elderly patients may be at greater risks from anesthetic exposure after either general or regional anesthesia.9 Evidence from animal models and cell culture studies suggests that exposure to anesthetics induces pathologic changes normally associated with AD, including increase in Aβ peptide and β-actin cleavage enzyme88; anesthesia-induced hypothermia also increased tau hyperphosphorylation by decreasing phosphatase 2A activity.95 In a transgenic mouse model of AD, exposure to halothane increased Aβ plaque deposition but was not associated with further deterioration of cognitive function.100 Anesthesia also appeared to have no effect on APP transcription and expression.101 Surgery under general anesthesia was associated with increased APP transcription and expression, Aβ expression, γ-secretase activity, and the hyperphosphorylated form of tau protein in aged mice.102

Animal studies suggest that anesthetics may be responsible for modifications in the brain that outlast their tenure within the body.103 Anesthetics directly affect memory processes and behavior.104,105 From preclinical studies, it is apparent that cognitive dysfunction can persist for several weeks after exposure to a commonly used anesthetic regimen106,107 and is associated with changes in gene expression in brain areas such as the hippocampus.108 Yet, some anesthetics do not produce any postexposure disturbance in cognition even in aged rats.109 Furthermore, randomized clinical trials in older patients undergoing major noncardiac surgery have reported similar incidence in POCD after regional or general anesthesia, thereby challenging the concept of anesthesia as a causative factor.7,9 However, anesthesia and surgery may potentiate each other's neurotoxic effects, leading to an increase in the severity of POCD.

Recent data suggest that tau levels can directly affect axonal transports, thus requiring Aβ as a copathogen to mediate neurotoxicity and cognitive impairment.110 Resulting neurotoxicity from the uncontrolled aggregation of these peptides ultimately disrupts brain homeostasis by limiting availability of nutrients and trophic factors to the neuronal population. Neuroinflammation, including activation of microglia cells, and release of proinflammatory mediators and serum proteins contribute to disease development in AD.111-113 Both environmental and genetic risk factors remain strong determinants for AD development.114 In particular, mutations in APP, APOE4, and presenilin 1 and 2 are predisposing genetic factors for abnormal Aβ production or deposition. Presence of the ApoE4 allele increases the abnormal accumulation of Aβ and tau and affects a number of pathways that affect neuronal activity and cell survival.115 Recently, compelling evidence from genome-wide association studies identified novel key genetic variants of molecular species involved in inflammatory signaling pathways that were associated with the development of AD and increased susceptibility for the late-onset variety.116,117

Preclinical studies are now uncovering novel mechanisms for surgical trauma, anesthesia, and neurodegeneration in triggering cognitive decline. Translational studies are required to confirm these findings in humans and test these new hypotheses.

A PROPOSED ROAD MAP FOR FUTURE STUDIES

Transformational research addressing postoperative cognitive decline will benefit from coordinated investigations using preclinical, clinical, and epidemiological experimental paradigms. The following sections describe the types of questions that can be addressed and the settings in which these can best be addressed; to comprehensively understand the causes and management of this important and ever-increasing clinical problem, bidirectional translation of studies at both preclinical and clinical levels will be required. As a result of this symposium we have been able to (1) advance our understanding of the pathogenesis of perioperative cognitive decline; (2) identify the risk factors associated with cognitive decline, including the contributions of neurodegeneration and of different disease states, including those with “hyperinflammatory diatheses” from either a heightened proinflammatory or an underperforming anti-inflammatory resolving arm; (3) identify biomarkers and standardize neuropsychological tests and imaging techniques that can predict vulnerable surgical patients; and (4) apply preemptive therapeutic strategies to thwart the devastation wrought by postoperative cognitive decline (Table 3).

TABLE 3.
Broad Categories That Need to Be Addressed to Elucidate Mechanisms, Risk Stratification, and Treatment of Postoperative Cognitive Decline

Preclinical Studies

Once animal models are better developed to address the multifactoriality of cognitive decline, they can be used to explore molecular mechanisms that can yield putative therapeutic targets that are amenable to manipulation and testing for efficacy (and safety) in patients. It will be necessary to confirm that factors that increase the likelihood of postoperative cognitive dysfunction in humans (including advanced age and postoperative pulmonary complications, especially of an infectious nature) are similar in animals. The exacerbating effect of the type of surgery (eg, orthopedic vs abdominal procedures) needs to be confirmed. Further development of animal models is needed to faithfully recapitulate the clinical setting by introducing the realism of the postoperative state, including sleep deprivation and the addition of sedatives and analgesics that have their own cognition-altering effects. Key changes noted in the animal models need to be sought in surgical patients to establish that the pathophysiologic processes are similar. Animal models can be used to address whether underlying neurodegenerative and vascular causes of dementia increase the risk of postoperative cognitive decline. Animal studies are needed to test the influence of diabetes, obesity, and underlying acute neurologic disease, such as stroke, on the development of postoperative cognitive decline. In the same vein, answering the question of the potential influence of a surgical procedure on disease progression in animal models of neurodegenerative disease becomes tractable. Perhaps the biggest controversy tying animal models of postoperative cognitive decline to the human illness is to address why animals recover from postoperative cognitive decline, whereas more than 10% of elderly patients appear to experience a progressive deterioration of cognitive function. At best, the existing animal models portray the acute delirium end of the postoperative cognitive decline spectrum, leaving the question of the existence of long-term cognitive decline after surgery for further model development.55 Even if one narrowly confines the applicability of the existing animal model, one still needs to understand why delirium does not occur after each surgical procedure in humans as it does in the animal models. In this respect the influence of factors that enhance the protective effect of “cognitive reserve” or exacerbate the pathophysiologic mechanisms can be directly explored. For example, the pathophysiology of “double hits” in the causation of postoperative delirium (produced by simulating 2 bouts of trauma as occur in hip fracture patients undergoing surgical stabilization) can be examined with greater temporal resolution to inform appropriate timing of the fracture stabilization procedure. The animal models can be used to determine the influence of different anesthetics (including regional vs general as well as different general anesthetic agents) in light of the differential neuroimmodulatory effects of anesthetic agents. Because we anticipate that preemptive neuromodulation is a possible therapeutic strategy, further understanding will be required to distinguish between inflammatory processes that facilitate healing and those that mediate cognitive dysfunction. In all likelihood, this discrimination will require very precise temporal resolution of the inflammatory processes initiated after surgical trauma and a careful elucidation of the proinflammatory vs the anti-inflammatory phase of the immune response to aseptic trauma.

Clinical Studies

As mentioned in the preceding section, it will be necessary to confirm that the changes that occur in animal models also occur in surgical patients. To progress in the clinical realm, both standardized testing and a definition of what constitutes an abnormality will be needed.37 It will be necessary to identify patients particularly at risk to develop an “enriched” patient population that will “power” therapeutic trials designed to test the safety and efficacy of an intervention. This will require identification of a characteristic phenotype either by sifting through routinely collected clinical information or by defining a biomarker associated with a higher risk. Although the former can be amenable to retrospective data mining of large clinical and administrative databases, the latter will require prospective studies. In this regard, 2 domains, genetic and neuroimaging, hold the greatest promise. The potential of genome-wide association studies is now being realized in the field of neuropsychiatric disorders with reduction in the costs of genetic testing.97,98 Neuroimaging can now be used to establish the preclinical and prodromal AD pathology for the development of neurodegenerative conditions, and its role in postoperative cognitive decline requires further investigation.118,119 Apart from the use of neuroimaging biomarkers (including amyloid load, as well as alterations in white matter and connectivity, and inflammatory markers), this powerful investigative modality may assist in the diagnosis (with different parameters including T1, T2, diffusion tensor imaging, arterial spin labeling perfusion magnetic resonance imaging, resting-state functional magnetic resonance imaging, contrast-enhancing studies, and positron emission tomography) of a condition whose existence is yet to be acknowledged by the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition).

Epidemiological Studies

Electronic health records, as well as the longitudinal databases that have been established by consortia such as the Alzheimer Disease Research Centers, will prove to be a valuable source of information on which hypotheses can be formulated for subsequent testing both in the preclinical and prospectively in the clinical settings. In particular, the contribution of ethnic, lifestyle, and socioeconomic factors and comorbidities to the development of postoperative cognitive decline can be interrogated. With the establishment of the American Society of Anesthesiologists–supported Anesthesia Quality Improvement database, there is a strong likelihood that associations will provide the grist for future hypotheses-testing studies.

CONCLUSION

We are likely to be confronted by an epidemic of postoperative cognitive decline that we are ill-equipped to address. We are only now beginning to scratch the surface of its proclivity, diagnosis, and causation and to contemplate possible strategies to prevent and treat this postoperative complication. It is axiomatic that for postoperative cognitive decline to be successfully counteracted, coordinated efforts will be required from experts in aging, neurodegeneration, vasculopathy, inflammation, neuroimaging, and the human genome working in conjunction with surgeons, anesthesiologists, and primary care physicians. Therefore, it is pivotal to establish multidisciplinary collaborations to confront a clinical problem with enormous patient suffering and societal consequences.

Acknowledgments

Dr Weiner reports the following financial disclosures: served on the following scientific boards in 2009, Elan/Wyeth Alzheimer's Immunotherapy Program North American Advisory Board, Novartis Misfolded Protein Scientific Advisory Board Meeting, Banner Alzheimer's Institute Alzheimer's Prevention Initiative Advisory Board Meeting, and Research Advisory Committee on Gulf War Veterans' Illnesses; in 2010, Lilly, Araclon and Institut Catala de Neurociencies Aplicades, Gulf War Veterans Illnesses Advisory Committee, VACO, and Biogen Idec; and in 2011, Pfizer. He did consulting for the following in 2009: Elan/Wyeth, Novartis, Forest, Ipsen, and Daiichi Sankyo, Inc; in 2010, Astra Zeneca, Araclon, Medivation/Pfizer, Ipsen, TauRx Therapeutics Ltd, Bayer Healthcare, Biogen Idec, Exonhit Therapeutics, SA, Servier, and Synarc; in 2011, Pfizer. He received funding for travel in 2009 from Elan/Wyeth Alzheimer's Immunotherapy Program North American Advisory Board, Alzheimer's Association, Forest, University of California, Davis, Tel-Aviv University Medical School, Colloquium Paris, Ipsen, Wenner-Gren Foundations, Social Security Administration, Korean Neurological Association, National Institutes of Health, Washington University at St. Louis, Banner Alzheimer's Institute, Clinical Trials on Alzheimer's Disease, Veterans Affairs Central Office, Beijing Institute of Geriatrics, Innogenetics, and New York University; in 2010, NeuroVigil, Inc, CHRU-Hopital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Lilly, University of California, San Diego-ADNI, Paris University, Institut Catala de Neurosciencies Aplicades, University of New Mexico School of Medicine, Ipsen, and CTAD (Clinical Trials on Alzheimer's Disease); in 2011, Pfizer, AD PD meeting, Paul Sabatier University, and Novartis. Dr Weiner serves on the Editorial Advisory Board for Alzheimer's & Dementia, and MRI; received honoraria in 2009 from American Academy of Neurology and Ipsen; in 2010, from NeuroVigil, Inc, and Insitut Catala de Neurociencies Aplicades. He receives Commercial Entities Research Support from Merck and Avid; Government Entities Research Support from DOD and VA; and has stock options in Synarc and Elan. The following organizations contribute to the Foundation for N1H and thus to the NIA—funded Alzheimer's Disease Neuroimaging Initiative: Abbott, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Anonymous Foundation, AstraZeneca, Bayer Healthcare, BioClinica Inc (ADNI 2), Bristol-Myers Squibb, Cure Alzheimer's Fund, Eisai, Elan, Gene Network Sciences, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly & Company, Medpace, Merck, Novartis, Pfizer Inc, Roche, Schering Plough, Synarc, and Wyeth.

REFERENCES

1. Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010;303(8):763-770. [PMC free article] [PubMed]
2. Etzioni DA, Liu JH, Maggard MA, Ko CY. The aging population and its impact on the surgery workforce. Ann Surg. 2003;238(2):170-177. [PubMed]
3. Alzheimer's Association 2011 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2011;7(2):1-63 http://www.alz.org/downloads/Facts_Figures_2011.pdf Accessed July 1, 2011.
4. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362(4):329-344. [PubMed]
5. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3(3):186-191. [PubMed]
6. Savage GH. Insanity following the use of anesthetics in operations. Br Med J. 1887;2(1405):1199-1200.
7. Williams-Russo P, Sharrock NE, Mattis S, Szatrowski TP, Charlson ME. Cognitive effects after epidural vs general anesthesia in older adults: a randomized trial. JAMA. 1995;274(1):44-50. [PubMed]
8. Moller JT, Cluitmans P, Rasmussen LS, et al. ; ISPOCD Investigators Long-term postoperative cognitive dysfunction in the elderly: ISPOCD1 study. Lancet. 1998;351(9106):857-861. [PubMed]
9. Rasmussen LS, Johnson T, Kuipers HM, et al. Does anaesthesia cause postoperative cognitive dysfunction? A randomised study of regional versus general anaesthesia in 438 elderly patients. Acta Anaesthesiol Scand. 2003;47(3):260-266. [PubMed]
10. Cohendy R, Brougere A, Cuvillon P. Anaesthesia in the older patient. Curr Opin Clin Nutr Metab Care. 2005;8(1):17-21. [PubMed]
11. Fong TG, Tulebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol. 2009;5(4):210-220. [PMC free article] [PubMed]
12. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA. 2004;291(14):1753-1762. [PubMed]
13. Milbrandt EB, Deppen S, Harrison PL, et al. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955-962. [PubMed]
14. Ely EW, Gautam S, Margolin R, et al. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001;27(12):1892-1900. [PubMed]
15. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787-1794. [PMC free article] [PubMed]
16. McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence and clinical course in older patients. J Am Geriatr Soc. 2003;51(5):591-598. [PubMed]
17. Robinson TN, Raeburn CD, Tran ZV, Angles EM, Brenner LA, Moss M. Postoperative delirium in the elderly: risk factors and outcomes. Ann Surg. 2009;249(1):173-178. [PubMed]
18. Jankowski CJ, Trenerry MR, Cook DJ, et al. Cognitive and functional predictors and sequelae of postoperative delirium in elderly patients undergoing elective joint arthroplasty. Anesth Analg. 2011;112(5):1186-1193. [PubMed]
19. Bohner H, Hummel TC, Habel U, et al. Predicting delirium after vascular surgery: a model based on pre- and intraoperative data. Ann Surg. 2003;238(1):149-156. [PubMed]
20. Benoit AG, Campbell BI, Tanner JR, et al. Risk factors and prevalence of perioperative cognitive dysfunction in abdominal aneurysm patients. J Vasc Surg. 2005;42(5):884-890. [PubMed]
21. Galanakis P, Bickel H, Gradinger R, Von Gumppenberg S, Forstl H. Acute confusional state in the elderly following hip surgery: incidence, risk factors and complications. Int J Geriatr Psychiatry. 2001;16(4):349-355. [PubMed]
22. Litaker D, Locala J, Franco K, Bronson DL, Tannous Z. Preoperative risk factors for postoperative delirium. Gen Hosp Psychiatry. 2001;23(2):84-89. [PubMed]
23. Yildizeli B, Ozyurtkan MO, Batirel HF, Kuscu K, Bekiroglu N, Yuksel M. Factors associated with postoperative delirium after thoracic surgery. Ann Thorac Surg. 2005;79(3):1004-1009. [PubMed]
24. Schuurmans MJ, Duursma SA, Shortridge-Baggett LM, Clevers GJ, Pel-Littel R. Elderly patients with a hip fracture: the risk for delirium. Appl Nurs Res. 2003;16(2):75-84. [PubMed]
25. Schneider F, Bohner H, Habel U, et al. Risk factors for postoperative delirium in vascular surgery. Gen Hosp Psychiatry. 2002;24(1):28-34. [PubMed]
26. Kain ZN, Caldwell-Andrews AA, Maranets I, et al. Preoperative anxiety and emergence delirium and postoperative maladaptive behaviors. Anesth Analg. 2004;99(6):1648-1654. [PubMed]
27. Yoshimura Y, Kubo S, Shirata K, et al. Risk factors for postoperative delirium after liver resection for hepatocellular carcinoma. World J Surg. 2004;28(10):982-986. [PubMed]
28. Leung JM, Sands LP, Wang Y, et al. Apolipoprotein E e4 allele increases the risk of early postoperative delirium in older patients undergoing noncardiac surgery. Anesthesiology. 2007;107(3):406-411. [PubMed]
29. Contin AM, Perez-Jara J, Alonso-Contin A, Enguix A, Ramos F. Postoperative delirium after elective orthopedic surgery. Int J Geriatr Psychiatry. 2005;20(6):595-597. [PubMed]
30. Leung JM, Sands LP, Paul S, Joseph T, Kinjo S, Tsai T. Does postoperative delirium limit the use of patient-controlled analgesia in older surgical patients? Anesthesiology. 2009;111(3):625-631. [PMC free article] [PubMed]
31. Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA. 1990;263(8):1097-1101. [PubMed]
32. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. JAMA. 1994;271(2):134-139. [PubMed]
33. Williams-Russo P, Urquhart BL, Sharrock NE, Charlson ME. Post-operative delirium: predictors and prognosis in elderly orthopedic patients. J Am Geriatr Soc. 1992;40(8):759-767. [PubMed]
34. Dyer CB, Ashton CM, Teasdale TA. Postoperative delirium: a review of 80 primary data-collection studies. Arch Intern Med. 1995;155(5):461-465. [PubMed]
35. Sasajima Y, Sasajima T, Uchida H, et al. Postoperative delirium in patients with chronic lower limb ischaemia: what are the specific markers? Eur J Vasc Endovasc Surg. 2000;20(2):132-137. [PubMed]
36. Caza N, Taha R, Qi Y, Blaise G. Chapter 26: The effects of surgery and anesthesia on memory and cognition. Prog Brain Res. 2008;169:409-422. [PubMed]
37. Newman S, Stygall J, Hirani S, Shaefi S, Maze M. Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology. 2007;106(3):572-590. [PubMed]
38. Steinmetz J, Christensen KB, Lund T, Lohse N, Rasmussen LS. Long-term consequences of postoperative cognitive dysfunction. Anesthesiology. 2009;110(3):548-555. [PubMed]
39. McKhann GM, Goldsborough MA, Borowicz LM, Jr, et al. Cognitive outcome after coronary artery bypass: a one-year prospective study. Ann Thorac Surg. 1997;63(2):510-515. [PubMed]
40. Johnson T, Monk T, Rasmussen LS, et al. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology. 2002;96(6):1351-1357. [PubMed]
41. Price CC, Garvan CW, Monk TG. Type and severity of cognitive decline in older adults after noncardiac surgery. Anesthesiology. 2008;108(1):8-17. [PMC free article] [PubMed]
42. Monk TG, Weldon BC, Garvan CW, et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology. 2008;108(1):18-30. [PubMed]
43. Abildstrom H, Rasmussen LS, Rentowl P, et al. ; ISPOCD group Cognitive dysfunction 1-2 years after non-cardiac surgery in the elderly. Acta Anaesthesiol Scand. 2000;44(10):1246-1251. [PubMed]
44. Canet J, Raeder J, Rasmussen LS, et al. Cognitive dysfunction after minor surgery in the elderly. Acta Anaesthesiol Scand. 2003;47(10):1204-1210. [PubMed]
45. Roach GW, Kanchuger M, Mangano CM, et al. ; Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996;335(25):1857-1863. [PubMed]
46. Abildstrom H, Christiansen M, Siersma VD, Rasmussen LS. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology. 2004;101(4):855-861. [PubMed]
47. Lelis RG, Krieger JE, Pereira AC, et al. Apolipoprotein E4 genotype increases the risk of postoperative cognitive dysfunction in patients undergoing coronary artery bypass graft surgery. J Cardiovasc Surg (Torino). 2006;47(4):451-456. [PubMed]
48. Heyer EJ, Wilson DA, Sahlein DH, et al. APOE-epsilon4 predisposes to cognitive dysfunction following uncomplicated carotid endarterectomy. Neurology. 2005;65(11):1759-1763. [PMC free article] [PubMed]
49. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 1996;335(25):1857-1863. [PubMed]
50. Wu SH, Wu XH, Lu C, Dong L, Zhou GP, Chen ZQ. Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells. Kidney Int. 2006;69(2):248-256. [PubMed]
51. Avidan MS, Xiong C, Evers AS. Postoperative cognitive decline: the un-substantiated phenotype [letter]. Anesthesiology. 2010;113(5):1246-1248. [PubMed]
52. Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT. Alzheimer's disease and cumulative exposure to anesthesia: a case-control study. J Am Geriatr Soc. 1994;42(2):198-201. [PubMed]
53. Gasparini M, Vanacore N, Schiaffini C, et al. A case-control study on Alzheimer's disease and exposure to anesthesia. Neurol Sci. 2002;23(1):11-14. [PubMed]
54. Fong TG, Jones RN, Shi P, et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology. 2009;72(18):1570-1575. [PMC free article] [PubMed]
55. Avidan MS, Searleman AC, Storandt M, et al. Long-term cognitive decline in older subjects was not attributable to noncardiac surgery or major illness. Anesthesiology. 2009;111(5):964-970. [PMC free article] [PubMed]
56. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A. 2010;107(47):20518-20522. [PubMed]
57. Cibelli M, Fidalgo AR, Terrando N, et al. Role of interleukin-1β in postoperative cognitive dysfunction. Ann Neurol. 2010;68(3):360-368. [PubMed]
58. Beloosesky Y, Hendel D, Weiss A, et al. Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci. 2007;62(4):420-426. [PubMed]
59. Buvanendran A, Kroin JS, Berger RA, et al. Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology. 2006;104(3):403-410. [PubMed]
60. Kobbe P, Vodovotz Y, Kaczorowski DJ, Mollen KP, Billiar TR, Pape HC. Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock. 2008;30(1):43-47. [PubMed]
61. Rosczyk HA, Sparkman NL, Johnson RW. Neuroinflammation and cognitive function in aged mice following minor surgery. Exp Gerontol. 2008;43(9):840-846. [PMC free article] [PubMed]
62. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25(3):154-159. [PubMed]
63. Annane D. Hippocampus: a future target for sepsis treatment! Intensive Care Med. 2009;35(4):585-586. [PubMed]
64. van Rossum D, Hanisch UK. Microglia. Metab Brain Dis. 2004;19(3-4):393-411. [PubMed]
65. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res. 2005;81(3):302-313. [PubMed]
66. Aloisi F. Immune function of microglia. Glia. 2001;36(2):165-179. [PubMed]
67. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119-145. [PubMed]
68. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6(4):193-201. [PubMed]
69. Terrando N, Monaco C, Feldmann M, Maze M. Unraveling the interactions between postoperative infection, surgery, and inflammation in post-operative cognitive dysfunction [abstract]. Eur J Anaesthesiol. 2010;27(47):1-2. [PubMed]
70. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-305. [PubMed]
71. Harris HE, Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006;7(8):774-778. [PubMed]
72. Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev. 2007;220:60-81. [PubMed]
73. Levy RM, Mollen KP, Prince JM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol. 2007;293(4):R1538-R1544. [PubMed]
74. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-342. [PubMed]
75. Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR. Early events in the recognition of danger signals after tissue injury. J Leukoc Biol. 2008;83(3):546-552. [PubMed]
76. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511. [PubMed]
77. Levy RM, Prince JM, Yang R, et al. Systemic inflammation and remote organ damage following bilateral femur fracture requires toll-like receptor 4. Am J Physiol Regul Integr Comp Physiol. 2006;291(4):R970-R976. [PubMed]
78. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock. 2006;26(5):430-437. [PubMed]
79. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162(7):3749-3752. [PubMed]
80. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428-435. [PubMed]
81. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81(1):1-5. [PubMed]
82. Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004;34(6):1503-1512. [PubMed]
83. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J. 2011;25(5):1441-1448. [PubMed]
84. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009;9(6):418-428. [PubMed]
85. Palop JJ, Mucke L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13(7):812-818. [PMC free article] [PubMed]
86. Xie Z, Tanzi RE. Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol. 2006;41(4):346-359. [PubMed]
87. Eckenhoff RG, Johansson JS, Wei H, et al. Inhaled anesthetic enhancement of amyloid-β oligomerization and cytotoxicity. Anesthesiology. 2004;101(3):703-709. [PubMed]
88. Xie Z, Culley DJ, Dong Y, et al. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid β-protein level in vivo. Ann Neurol. 2008;64(6):618-627. [PMC free article] [PubMed]
89. Planel E, Krishnamurthy P, Miyasaka T, et al. Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci. 2008;28(48):12798-12807. [PMC free article] [PubMed]
90. Xie Z, Dong Y, Maeda U, et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid β protein levels. Anesthesiology. 2006;104(5):988-994. [PubMed]
91. Dong Y, Zhang G, Zhang B, et al. The common inhalational anesthetic sevoflurane induces apoptosis and increases β-amyloid protein levels. Arch Neurol. 2009;66(5):620-631. [PMC free article] [PubMed]
92. Zhang B, Dong Y, Zhang G, et al. The inhalation anesthetic desflurane induces caspase activation and increases amyloid β-protein levels under hypoxic conditions. J Biol Chem. 2008;283(18):11866-11875. [PubMed]
93. Zhen Y, Dong Y, Wu X, et al. Nitrous oxide plus isoflurane induces apoptosis and increases β-amyloid protein levels. Anesthesiology. 2009;111(4):741-752. [PMC free article] [PubMed]
94. Xie Z, Dong Y, Maeda U, et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid β-protein accumulation. J Neurosci. 2007;27(6):1247-1254. [PubMed]
95. Planel E, Bretteville A, Liu L, et al. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009;23(8):2595-2604. [PubMed]
96. Whittington RA, Virag L, Marcouiller F, et al. Propofol directly increases tau phosphorylation. PLoS ONE. 2011;6(1):e16648. [PMC free article] [PubMed]
97. Bittner EA, Yue Y, Xie Z. Brief review: anesthetic neurotoxicity in the elderly, cognitive dysfunction and Alzheimer's disease. Can J Anaesth. 2011;58(2):216-223. [PubMed]
98. Tang J, Eckenhoff MF, Eckenhoff RG. Anesthesia and the old brain. Anesth Analg. 2010;110(2):421-426. [PubMed]
99. Rappaport B, Mellon RD, Simone A, Woodcock J. Defining safe use of anesthesia in children. N Engl J Med. 2011;364(15):1387-1390. [PubMed]
100. Bianchi SL, Tran T, Liu C, et al. Brain and behavior changes in 12-month-old Tg2576 and nontransgenic mice exposed to anesthetics. Neurobiol Aging. 2008;29(7):1002-1010. [PubMed]
101. Palotas M, Palotas A, Bjelik A, et al. Effect of general anesthetics on amyloid precursor protein and mRNA levels in the rat brain. Neurochem Res. 2005;30(8):1021-1026. [PubMed]
102. Wan Y, Xu J, Meng F, et al. Cognitive decline following major surgery is associated with gliosis, β-amyloid accumulation, and tau phosphorylation in old mice. Crit Care Med. 2010;38(11):2190-2198. [PubMed]
103. Futterer CD, Maurer MH, Schmitt A, Feldmann RE, Jr, Kuschinsky W, Waschke KF. Alterations in rat brain proteins after desflurane anesthesia. Anesthesiology. 2004;100(2):302-308. [PubMed]
104. Wiklund A, Granon S, Faure P, Sundman E, Changeux JP, Eriksson LI. Object memory in young and aged mice after sevoflurane anaesthesia. Neuroreport. 2009;20(16):1419-1423. [PubMed]
105. Wang DS, Orser BA. Inhibition of learning and memory by general anesthetics. Can J Anaesth. 2011;58(2):167-177. [PubMed]
106. Culley DJ, Baxter M, Yukhananov R, Crosby G. The memory effects of general anesthesia persist for weeks in young and aged rats. Anesth Analg. 2003;96(4):1004-1009. [PubMed]
107. Culley DJ, Baxter MG, Yukhananov R, Crosby G. Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology. 2004;100(2):309-314. [PubMed]
108. Culley DJ, Yukhananov RY, Xie Z, Gali RR, Tanzi RE, Crosby G. Altered hippocampal gene expression 2 days after general anesthesia in rats. Eur J Pharmacol. 2006;549(1-3):71-78. [PubMed]
109. Lee IH, Culley DJ, Baxter MG, Xie Z, Tanzi RE, Crosby G. Spatial memory is intact in aged rats after propofol anesthesia. Anesth Analg. 2008;107(4):1211-1215. [PubMed]
110. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents Abeta-induced defects in axonal transport. Science. 2010;330(6001):198. [PMC free article] [PubMed]
111. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 1995;21(2):195-218. [PubMed]
112. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6(5):404-416. [PubMed]
113. O'Bryant SE, Xiao G, Barber R, et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol. 2010;67(9):1077-1081. [PMC free article] [PubMed]
114. Belbin O, Carrasquillo MM, Crump M, et al. Investigation of 15 of the top candidate genes for late-onset Alzheimer's disease. Hum Genet. 2011;129(3):273-282. [PMC free article] [PubMed]
115. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(11):4725-4727. [PubMed]
116. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-441. [PMC free article] [PubMed]
117. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-435. [PMC free article] [PubMed]
118. Pike KE, Savage G, Villemagne VL, et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(Pt 11):2837-2844. [PubMed]
119. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452. [PubMed]

Articles from Mayo Clinic Proceedings are provided here courtesy of The Mayo Foundation for Medical Education and Research